Kickbacks, courtesies or cost-effectiveness?: Application of the medicare antikickback law to the marketing and promotional practices of drug and medical device manufacturers

Thomas N.Bulleit; Joan H.Krause

首页> 外文期刊>Food and Drug Law Journal >Kickbacks, courtesies or cost-effectiveness?: Application of the medicare antikickback law to the marketing and promotional practices of drug and medical device manufacturers

【24h】

Kickbacks, courtesies or cost-effectiveness?: Application of the medicare antikickback law to the marketing and promotional practices of drug and medical device manufacturers

机译：回扣，礼节还是成本效益？：医疗保险反回扣法在药品和医疗器械制造商的营销和促销活动中的适用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Food and Drug Law Journal》 |1999年第3期|共45页
作者
Thomas N.Bulleit; Joan H.Krause;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类食品工业;
关键词
drug; law;

机译：毒品;法律;

相似文献

外文文献
专利

1. Kickbacks, courtesies or cost-effectiveness?: Application of the medicare antikickback law to the marketing and promotional practices of drug and medical device manufacturers [J] . Thomas N.Bulleit, Joan H.Krause Food and Drug Law Journal . 1999,第3期

机译：回扣，礼节还是成本效益？：医疗保险反回扣法在药品和医疗器械制造商的营销和促销活动中的适用
2. Medical Device Immunity: Should Promotion of Off-Label Uses Leave Medical Device Manufacturers Vulnerable to Unlimited Liability? [J] . Palmer Phillip G. Jr. The Journal of legal medicine . 2014,第4期

机译：医疗器械的豁免权：是否应限制使用非标签用途，从而使医疗器械制造商不承担无限责任？
3. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. [J] . Mullins CD, Seal B, Seoane Vazquez E, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2010,第1期

机译：在成本效益分析中衡量药物成本的良好研究实践：Medicare，Medicaid和其他美国政府付款人的观点：ISPOR药物成本工作组报告-第四部分。
4. Drug Piracy I: Legitimate Pharmacy Compounding, Pioneer and Generic Drugs and Registered Products, and Medical Devices? What are the Facts and how can this Affect My Practice? [C] . Joseph J. Bertone Annual Conference of American Association of Bovine Practitioners . 2004

机译：药物盗版我：合法药房复合，先锋和通用药物和注册产品，以及医疗器械吗？这是什么事实以及这会如何影响我的练习？
5. How pharmaceutical marketing communications affect prescribing practices, is there an ethical conflict? Focus on physicians, medical clerks and drug representatives: The case of the Western side of Puerto Rico. [D] . Rodriguez Mari, Shirley S. 2008

机译：药品营销传播如何影响处方实践，是否存在道德冲突？关注医生，医疗人员和毒品代表：波多黎各西侧的情况。
6. A 1-year cross-sectional analysis of non-interventional post-marketing study protocols submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) [O] . Beatrice K. J. G. von Jeinsen, Thomas Sudhop -1

机译：提交给德国联邦药品和医疗器械研究所（BfArM）的非介入式上市后研究方案的1年横断面分析
7. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV [O] . Mullins C. Daniel, Seal Brian, Seoane-Vazquez Enrique, 2010

机译：在成本效益分析中衡量药物成本的良好研究实践：Medicare，Medicaid和其他美国政府付款人的观点：ISPOR药物成本工作组报告-第IV部分
8. Federal Register Volume 61 No. 195, Monday, October 7, 1996 Rules andRegulations. Part 7. Department of Health and Human Services, Food and Drug Administration. 21 CFR Parts 808, 812, and 820 Medical Devices; Current Good Manufacturing Practice (CGMP); Fi [R] . 1997

机译：联邦登记册第61卷第195号，1996年10月7日，星期一规则和规定。第7部分。健康与人类服务部，食品药品管理局。 21 CFR parts 808,812和820医疗器械;现行良好生产规范（CGmp）;网络连接

Kickbacks, courtesies or cost-effectiveness?: Application of the medicare antikickback law to the marketing and promotional practices of drug and medical device manufacturers

著录项

相似文献

相关主题

期刊订阅